Document:

Exhibit 10.27

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

OXYSURE
SYSTEMS, INC.

 

	Warrant
    Shares: [REQUIRES COMPLETION]	Initial
    Exercise Date: December ___, 2014

 

Warrant
No: [REQUIRES COMPLETION]

  

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [REQUIRES COMPLETION]
or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and
the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”)
and on or prior to the close of business on the four (4) year anniversary of the Initial Exercise Date (the “Termination
Date”) but not thereafter, to subscribe for and purchase from Oxysure Systems, Inc., a Delaware corporation (the “Company”),
up to [REQUIRES COMPLETION] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common
Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b).

 

Section
1.    Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that
certain Securities Purchase Agreement (the “Purchase Agreement”), dated December ___, 2014, among the Company
and the purchasers signatory thereto.

 

Section
2.    Exercise.

 

a)   Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of
the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books
of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto. Within two (2) Trading Days following
the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable
Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure
specified in Section 2(c) below is specified in the applicable Notice of Exercise. Notwithstanding anything herein to the contrary
(although the Holder may surrender the Warrant to, and receive a replacement Warrant from, the Company), the Holder shall not
be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for
cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises
of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect
of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date
of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one (1) Trading Day of delivery
of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions
of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

    	1

    	 

    

 

b)   Exercise Price. The initial exercise price per share of the Common Stock under this Warrant shall be $1.20, subject
to adjustment hereunder (the “Exercise Price”).

 

c)   Cashless Exercise. If at any time commencing 180 days after the Initial Exercise Date, there is no effective registration
statement registering, or no current prospectus available for the resale of the Warrant Shares by the Holder, then this Warrant
may also be exercised at the Holder’s election, in whole or in part, at such time by means of a “cashless exercise”
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B)
(X)] by (A), where:

 

(A)
= the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
exercise,” as set forth in the applicable Notice of Exercise;

 

(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and

 

(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.

 

Notwithstanding
anything herein to the contrary, on the Termination Date, unless the Holder notifies the Company otherwise, if there is no effective
Registration Statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then
this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).

 

    	2

    	 

    

 

d)   Mechanics of Exercise.

 

              
i.            Delivery of Certificates Upon Exercise. Certificates
for shares purchased hereunder shall be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s
prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”)
if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the
issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless
exercise and Rule 144 is available, and otherwise by physical delivery to the address specified by the Holder in the Notice of
Exercise by the date that is three (3) Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise,
(B) surrender of this Warrant (if required) and (C) payment of the aggregate Exercise Price as set forth above (including by cashless
exercise, if permitted) (such date, the “Warrant Share Delivery Date”). The Warrant Shares shall be deemed
to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder
of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise
Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi)
prior to the issuance of such shares, having been paid. The Company understands that a delay in the delivery of the Warrant Shares
after the Warrant Share Delivery Date could result in economic loss to the Holder. As compensation to the Holder for such loss,
the Company agrees to pay (as liquidated damages and not as a penalty) to the Holder for late issuance of Warrant Shares upon
exercise of this Warrant the proportionate amount of $10 per Trading Day (increasing to $20 per Trading Day after the fifth (5th)
Trading Day) after the Warrant Share Delivery Date for each $1,000 of Exercise Price of Warrant Shares for which this Warrant
is exercised which are not timely delivered. The Company shall pay any payments incurred under this Section in immediately available
funds upon demand. Furthermore, in addition to any other remedies which may be available to the Holder, in the event that the
Company fails for any reason to effect delivery of the Warrant Shares by the Warrant Share Delivery Date, the Holder may revoke
all or part of the relevant Warrant exercise by delivery of a notice to such effect to the Company, whereupon the Company and
the Holder shall each be restored to their respective positions immediately prior to the exercise of the relevant portion of this
Warrant, except that the liquidated damages described above shall be payable through the date notice of revocation or rescission
is given to the Company.

 

              
ii.            Delivery of New Warrants Upon Exercise. If this Warrant
shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate,
at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all
other respects be identical with this Warrant.

 

              
iii.          Rescission Rights. If the Company fails to cause the Transfer
Agent to transmit to the Holder a certificate or the certificates representing the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right, at any time prior to issuance of such Warrant Shares,
to rescind such exercise.

 

    	3

    	 

    

 

              
iv.           Compensation for Buy-In on Failure to Timely Deliver Certificates
Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to
transmit to the Holder a certificate or the certificates representing the Warrant Shares pursuant to an exercise on or before
the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction
or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a
sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would
have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to
the terms hereof.

 

              
v.           No Fractional Shares or Scrip. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder
would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in
respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole
share.

 

              
vi.          Charges, Taxes and Expenses. Issuance of certificates for Warrant
Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the
issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued
in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in
the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered
for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require,
as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall
pay all Transfer Agent fees required for same-day processing of any Notice of Exercise.

 

              
vii.         Closing of Books. The Company will not close its stockholder books
or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

 

    	4

    	 

    

 

e)                 
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence, the number
of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock
issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any
other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on
conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. 
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall
be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and
of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic
or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. 
Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days’
prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any such increase or decrease will not be effective until the 61st day
after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which
may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to
a successor holder of this Warrant.

 

    	5

    	 

    

 

Section
3.    Certain Adjustments.

 

a)    Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant or pursuant to any of the other Transaction Documents), (ii) subdivides outstanding shares of Common
Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock
into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock
of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number
of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon
exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain
unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.

 

b)    Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could
have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

c)    Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders
of Common Stock (and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights
or warrants to subscribe for or purchase any security other than the Common Stock (which shall be subject to Section 3(b)), then
in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record
date fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall
be the VWAP determined as of the record date mentioned above, and of which the numerator shall be such VWAP on such record date
less the then per share fair market value at such record date of the portion of such assets or evidence of indebtedness so distributed
applicable to one outstanding share of the Common Stock as determined by the Board of Directors in good faith. In either case
the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences of indebtedness
so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment shall be made whenever any
such distribution is made and shall become effective immediately after the record date mentioned above.

 

    	6

    	 

    

 

d)    Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making
or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the
Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant) the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number
of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the
Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of
a Fundamental Transaction that is (1) an all cash transaction, (2) a “Rule 13e-3 transaction” as defined in Rule 13e-3
under the Exchange Act, or (3) a Fundamental Transaction involving a person or entity not traded on a national securities exchange
or trading market (with such exchange or market including, without limitation, the Nasdaq Global Select Market, the Nasdaq Global
Market, or the Nasdaq Capital Market, The New York Stock Exchange, Inc., the NYSE or Amex), the Company or any Successor Entity
(as defined below) shall, at the Holder’s option, exercisable concurrently with the consummation of the Fundamental Transaction,
purchase this Warrant from the Holder by paying to the Holder the higher of (i) an amount of cash equal to the Black Scholes Value
of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction, or (ii)
the positive difference between the cash per share paid in such Fundamental Transaction minus the then in effect Exercise Price.
“Black Scholes Value” means the value of the unexercised portion of this Warrant based on the Black and Scholes
Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest
rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100
day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the
price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental
Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date. The Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under
this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is
exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead
to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the
Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named
as the Company herein.

 

    	7

    	 

    

 

e)    Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f)     Notice to Holder.

 

              
i.            Adjustment to Exercise Price. Whenever the Exercise
Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting
forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth
a brief statement of the facts requiring such adjustment.

 

              
ii.            Notice to Allow Exercise by Holder. If (A) the Company
shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special
nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders
of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights,
(D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock,
any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of
the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, or (E) the Company
shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each
case, to the extent that such information constitutes material non-public information (as determined in good faith by the Company)
the Company shall follow the procedure described in Section 13 of the Subscription Agreement and shall deliver to the Holder at
its last address as it shall appear upon the Warrant Register of the Company, at least fifteen (15) calendar days prior to the
applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for
the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of
which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or
in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent
that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of
the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.
The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

Section
4.    Transfer of Warrant.

 

a)    Transferability. Subject to compliance with any applicable securities laws and the provisions of the Purchase Agreement,
this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

    	8

    	 

    

 

b)    New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.

 

c)    Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section
5.    Miscellaneous.

 

a)    No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).

 

b)    Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)    Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next
succeeding Trading Day.

 

    	9

    	 

    

 

d)    Authorized Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant
Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be
necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant
Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase
rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued,
fully paid and non-assessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)    Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the provisions of the Purchase Agreement.

 

f)     Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
or unless exercised in a cashless exercise when Rule 144 is available, and the Holder does not utilize cashless exercise, will
have restrictions upon resale imposed by state and federal securities laws.

 

g)    Non-waiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting
any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any
provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.

 

    	10

    	 

    

 

h)    Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered in accordance with the notice provisions of the Purchase Agreement.

 

i)     Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.

 

j)     Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)    Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)     Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holders of not less than a majority of the outstanding Warrants issued pursuant to the Purchase Agreement.

 

m)   Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)    Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	11

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	OXYSURE SYSTEMS,
    INC.
	 	 
	 	By:	 
	 	 	Name: Julian T. Ross

        Title:   CEO

 

    	12

    	 

    

 

NOTICE
OF EXERCISE

 

To:OXYSURE
SYSTEMS, INC.

 

(1)  
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)  
Payment shall take the form of (check applicable box):

 

☐ in
lawful money of the United States; or

 

☐
[if permitted] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).

 

(3)  
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name
as is specified below:

 

_______________________________

 

(4)  
After giving effect to this Notice of Exercise, the undersigned will not have exceeded the Beneficial Ownership Limitation.

 

The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

  

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: _______________________________________________________________________

 

Signature
of Authorized Signatory of Investing Entity: _________________________________________________

 

Name
of Authorized Signatory: ___________________________________________________________________

 

Title
of Authorized Signatory: ____________________________________________________________________

 

Date:
_______________________________________________________________________________________

 

    	 

    	 

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

OXYSURE
SYSTEMS, INC.

 

FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

	 	 whose address is

 

	 
	 
	 
	 

 

Dated:
______________, _______

 

	 	Holder’s Signature: 	 
	 	 	 
	 	Holder’s
Address:	 
	 	 	 
	 	 	 

 

	Signature Guaranteed: 	 

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those
acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.Exhibit 10.29

 

 

 

EXCLUSIVE DISTRIBUTION AGREEMENT

 

This Distribution Agreement (together with
its related exhibits, the “Agreement”) is made and executed this                                         , (the “Effective Date”)
by and between OXYSURE® SYSTEMS, INC. (“OxySure” or “OxySure®”), a Delaware,
USA corporation with its primary place of business located at 10880 John W. Elliott Drive, Suite 600, Frisco, Texas, 75033 USA
and AJAD MEDICAL (the “Distributor”), located                                                

 

OxySure® and Distributor intend
to establish Distributor as a distributor of those products (the “Products”) identified in Exhibit A within the territory
(the “Territory”) and channel (the “Channel”) identified in Exhibit B. Accordingly, OxySure®
and Distributor agree as follows:

 

		1.	Appointment and Term

 

		1.1	For the term of this Agreement, OxySure® appoints Distributor as the exclusive
distributor for the Products in the Territory and Channel. Distributor’s appointment is for an initial term of three (3)
years from the Effective Date, renewable thereafter for successive one-year periods unless terminated in terms hereof.

 

		1.2	The appointment of Distributor is personal to Distributor and accordingly (a) the rights, duties
and privileges of Distributor under this Agreement are not assignable in any way whatsoever without the prior written consent of
OxySure.

 

		2.	Distributor Responsibilities

 

		2.1	Both parties acknowledge that open communications and the sharing of information are important
to fully develop the market, gain insight into the market’s needs and develop appropriate market strategies. To this end,
the parties agree to cooperate and openly communicate with each other in furtherance of these objectives.

 

		2.2	Distributor will use its best efforts to develop the Territory and Channel market and promote the
sales of Products within the Territory and Channel. Distributor will not, without OxySure’s prior written consent, (a) either
advertise the Products for sale or sell the Products outside the Territory or Channel, or (b) advertise the Products for sale inside
the Territory or Channel if the Products are ultimately destined for delivery outside the Territory or Channel or to someone whom
Distributor has reason to believe will use the Products or resell them outside the Territory or Channel.

 

		2.3	Distributor will maintain sufficient inventory of Products to enable the prompt delivery of Products
to its Customers. On or before the fifth day of each month, Distributor shall provide OxySure with a six-month rolling forecast
providing a reasonable estimate of the Products Distributor expects to sell over the subsequent six month period (the “Forecast”).
In addition, Distributor must comply, at a minimum, with the Minimum Net Purchases requirement set forth in Section 4.

 

		2.4	Distributor will maintain an adequately trained sales organization, which will include at least
one OxySure Product specialist, to enable Distributor to fulfill its obligations under Section 2.2 of this Agreement. Distributor
will further maintain an organized and well stocked collection of technical and marketing information and materials for distribution
to prospective Customers. Distributor shall cover the Territory and Channel with diligent, adequate and reasonable sales activities,
including advertising, distribution of technical and sales materials, exhibitions, demonstrations and other methods of promoting
sales of the Products. Distributor will bear all expenses incurred in connection with these activities.

 

OxySure®
Distribution Agreement

    	Page 1 of 22

    	 

    

 

		2.5	Distributor will employ and maintain sufficiently trained personnel to provide technical support
for the Products, such support including, but not being limited to, the use and limited maintenance of the Products. Distributor
and OxySure will cooperate to ensure such personnel become and remain adequately trained and qualified pursuant to Section 3.2.

 

		2.6	Distributor will maintain a reasonable number of demonstration Products for demonstration to prospective
and existing Customers. Distributors will not sell any demonstration Product(s) to a Customer.

 

		2.7	OxySure does not authorize Distributor to make, and Distributor will not make, any guaranty or
warranty with respect to any Product. OxySure will provide all Product warranties, if any, directly and in writing to the Customer.
Distributor will make no representations as to Product quality, performance, capabilities and the like except as OxySure expressly
authorizes in writing, such as through published, product specifications.

 

		2.8	Distributor agrees to avoid all activities that might place Distributor in a position of adverse
interest or divided loyalty with OxySure or Distributor’s obligations as defined herein.

 

		2.9	In addition to Section 8, Distributor will provide to OxySure upon discovery by Distributor and,
on OxySure’s request, any information regarding:

 

	 	(a)	the infringement, perceived infringement, unauthorized manufacture, use or marketing or misuse of OxySure’s intellectual
property, Proprietary Information (as defined in Section 10 below), and/or Products;

 

		(b)	activities within the Territory or Channel marketplace that affect the sales of the Products;

 

		(c)	any inquiries or orders for any of the Products to be delivered outside the Territory or Channel
or for delivery in the Territory or Channel for ultimate use outside the Territory or Channel;

 

		(d)	any observations concerning recurrent issues with the Products;

 

		(e)	any changes in the management or ownership of Distributor; and

 

		(f)	in the event Distributor learns of information relating to an alleged malfunction of or an infliction
of an injury by a Product, Distributor shall promptly notify OxySure and provide all known information as well as assist OxySure
in any reasonable investigation concerning such allegations. Distributor will abide by all Distributor-specific governmental reporting
requirements as imposed by the United States Food and Drug Administration or any other relevant local, state or federal governmental
body.

 

		2.10	Distributor will maintain information regarding the sale of each Product, including, but not limited
to: Customer names and addresses, product identification information (including but not limited to lot numbers, batch numbers,
SKU numbers, and expiration dates) and a description of the products provided. Distributor will also maintain all books of accounts,
documents, correspondence, records, or the like, relating to any transaction involving the Products. In the event OxySure desires
to communicate regulatory or other information to Customers, or otherwise notify Customers for any reason, Distributor will use
the Customer information that it maintains to send such notice or communication on behalf of OxySure in a timely manner. Further,
Distributor will make such Customer information available to OxySure to the extent necessary for OxySure to comply with relevant
laws, rules, regulations, and judicial or administrative orders.

 

		2.11	Distributor shall furnish to OxySure copies of all proposed advertising, technical, sales, and
other materials relating to the Products and refrain from using and/or discontinue the use of any such materials which in the sole
opinion of OxySure are false or misleading or may subject OxySure to liability.

 

		2.12	Distributor agrees to carry out all of its obligations to OxySure promptly and in good faith. Time
is of the essence in this Agreement.

 

		2.13	Distributor shall not take any action that may result in denigrating, tarnishing or otherwise adversely
affecting the reputation or goodwill of OxySure. Without limiting the foregoing, Distributor agrees that it shall not (a) explicitly
or implicitly misrepresent any feature or function of the Product, (b) make unauthorized claims or statements related to the Products,
or (c) make any false statements related to the Product or OxySure.

 

OxySure®
Distribution Agreement

    	Page 2 of 22

    	 

    

 

		2.14	In performing its obligations hereunder, Distributor shall comply with any and all relevant laws,
rules, regulations, and restrictions, including, but not limited to, any that may be specifically applicable to the Products and
the sale thereof.

 

		2.15	Distributor may not market, promote, distribute, advertise, offer, sell or otherwise provide any
Product through a Web site, email communications, or other electronic method or medium unless each of the parties have executed
the “Internet Distribution Attachment” attached to this Agreement. Notwithstanding the foregoing, Distributor may provide
Product materials, pricing and invoices via email to a Customer, provided that such email communications are in response to direct
Customer inquiries and are not part of a marketing or other promotional campaign or effort.

 

		2.16	Distributor shall, immediately upon the Effective Date pursue and obtain any and all regulatory
approvals (“Regulatory Approvals”) required in the Territory for at least Part Numbers 615-00 and 615-01 illustrated
in Exhibit A, at its own expense and cost. Any regulatory approvals will be applied for, issued and held in the name of OxySure
Systems, Inc.

 

	2.17	Intentionally omitted.

 

	3.	OxySure’s Responsibilities

 

		3.1	OxySure® will provide such technical and marketing information as OxySure deems
appropriate, or upon Distributor’s request. Any applicable costs for printed materials shall be borne by Distributor, unless
otherwise agreed by the parties.

 

		3.2	OxySure will provide training in the use, limited maintenance and technical aspects of the Products,
including supplemental training relating to new products as such are introduced, at OxySure’s place of business identified
hereinabove or as otherwise agreed by the parties. The cost of transportation, meals, and lodging during the training shall be
borne by the Distributor. Further, OxySure will provide online or web-based training and support from time to time.

 

		3.3	OxySure will be under no obligation to Distributor to manufacture, sell or supply, or to continue
to manufacture, sell or supply any of the Products, or to continue or modify any model or type of any of the Products.

 

		3.4	OxySure agrees to carry out all its obligations to the Distributor promptly and in good faith,
and shall use commercially reasonable efforts to support Distributor’s authorized sales efforts in the Territory and Channel.

 

		3.5	OxySure will provide its best efforts to assist and support Distributor in obtaining the Regulatory
Approvals.

 

		3.6	OxySure will provide its best efforts to assist and support Distributor in developing translations
of marketing collateral, labels and other marketing materials

 

	4.	Minimum Net Purchases

 

Distributor shall purchase, in the
specified period, no less than the amount of the Minimum Net Purchases (herein so called) set forth in Exhibit C. Exhibit C will
be amended at the beginning of each Renewal Term, subject to continuation of this Agreement as provided herein, to reflect the
agreed upon Minimum Net Purchases for the succeeding year. In the event the parties are unable to agree on the Minimum Net Purchases
for any Renewal Term no less than thirty (30) days prior to the commencement of such Renewal Term, OxySure shall have the right,
in its sole discretion, to establish the Minimum Net Purchases for such Renewal Term. In the event Distributor does not purchase
the agreed upon Minimum Net Purchases in the Initial Term or any Renewal Term, Distributor shall be in default under this Agreement
for cause.

 

OxySure®
Distribution Agreement

    	Page 3 of 22

    	 

    

 

	5.	Products, Pricing, Packaging, Title

 

		5.1	OxySure may, in its sole discretion, effect any change with respect to a Product or amend the Products
offerings set forth on Exhibit A, provided, that with respect to any material change (e.g., amending the Product offerings set
forth on Exhibit A, OxySure shall provide Distributor with thirty (30) days prior written notice. OxySure will continue to honor
orders for any Products removed from Exhibit A for three (3) months after the removal date provided (a) the orders are submitted
to fill quotes outstanding on or before the date of removal of such Product(s), and (b) the removed Products have not been discontinued
and are no longer available.

 

		5.2	Prices for Products will be as set forth on Exhibit G, as amended from time to time by OxySure’s
official price list (“Product Price List”).

 

		5.3	Any suggested resale prices shown in the Product Price List are to be construed as a guideline
only. The Distributor is free to determine its own resale prices of the Products. Notwithstanding the immediately preceding sentence,
Distributor may not publish or display a price lower than the manufacturer suggested resale prices (MSRP) shown on the Product
Price Lists on (a) any Internet site, unless the parties have executed the Internet Distribution Attachment set forth on Exhibit
H, (b) any email advertisement, or (c) any newspaper, newsletter, magazine or other published source provided to more than 25 people.
Further, Distributor will clearly state whether pricing is based on bulk or bundled purchases. Distributor shall avoid any pricing
policies that would adversely affect the image of the Products.

 

		5.4	Distributor will abide by those terms for payment as set forth in Exhibit D.

 

		5.5	Any credits issued by OxySure will be handled as a separate financial transaction from the original
invoice, and payments under the invoice may not be withheld or delayed because of any credit. Distributor shall not reduce any
payment to OxySure to account for an anticipated, disputed or unauthorized credit. For credit, Distributor will submit a written
credit request within thirty (30) days from the date of Distributor’s invoice for the related transaction. Any credit request
will be based on the price shown on the then current Product Price List, or the actual net price paid by Distributor, whichever
is lower. Upon notification by OxySure of a discrepancy in a credit request, Distributor has thirty (30) days to resolve such discrepancy
and pay any amount due to OxySure.

 

		5.6	All Products shall be delivered to Distributor F.O.B. OxySure’s principal place of business.

 

	6.	Returns

 

Distributor may return Products in
accordance with (a) any applicable limited warranty, if effective (see Section 7.1), or (b) the return policy set forth in Exhibit
E. OxySure may amend or change its return policy upon thirty (30) days written notice to Distributor.

 

	7.	Limited Warranty and Warranty Service

 

		7.1	OxySure provides a Customer limited warranty for the Products. The terms of the Customer limited
warranty are set forth in the documentation provided with the Products, a copy of such being provided in Exhibit F. Upon any amendment
of or addition to the end user limited warranty, OxySure shall provide Distributor with written notice of such change. Distributor
shall strictly comply with the terms and provisions of Section 2.7 relating to the issuance of warranties, guaranties or representations.
OXYSURE MAKES NO OTHER WARRANTIES OF ANY KIND WHATSOEVER WITH REGARD TO THE PRODUCTS, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY
OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

 

		7.2	Distributor shall not repair, attempt to repair, modify, attempt to modify, or the like, any Products.
Distributor shall return any defective or allegedly defective Product to OxySure for assessment and repair (if applicable).

 

		7.3	For the purpose of technical support, OxySure hereby grants Distributor a license to use any OxySure-provided
Proprietary Information supplied to carry out its obligations under this Agreement. Such Proprietary Information, or any copies
or versions in any form or language, shall in all cases remain the property of OxySure. The confidentiality of such Proprietary
Information is governed by Section 10.

 

OxySure®
Distribution Agreement

    	Page 4 of 22

    	 

    

 

	8.	Reports and Audits

 

		8.1	COMMENCING DURING THE INITIAL TERM, DISTRIBUTOR WILL PROVIDE OXYSURE WRITTEN MONTHLY REPORTS, SUCH
REPORTS TO INCLUDE, AT A MINIMUM, THE AMOUNT OF INVENTORY ON HAND, INDIVIDUAL CUSTOMER SALES OR DISTRIBUTION ACTIVITY AND SALES
DATA FOR (A) THE PRECEDING MONTH AND (B) THE YEAR TO DATE, SUCH REPORT BEING PROVIDED BY THE 10TH DAY OF EACH MONTH.
 

 

		8.2	Distributor shall provide OxySure with an annual market survey and other written reports from time
to time upon OxySure’s reasonable request and specification. Such reports shall address account strategies, account conditions,
Customer feedback and evaluations, or other like information.   

 

		8.3	OxySure may have an authorized OxySure representative, at OxySure’s expense, audit Distributor’s
records concerning sales data and inventory records as such relates to the Products and any warranty service performed with respect
to the Products and any components. Upon prior written notice, Distributor will provide reasonable access to such records during
normal business hours at Distributor’s office or other site. Distributor agrees to maintain all such records for a minimum
of five (5) years and, prior to destroying or disposing of any such records (whether before or after the expiration of five (5)
years) Distributor shall provide OxySure with thirty (30) days’ written notice and afford OxySure the option to take possession
of such records, at OxySure’s sole discretion.

 

	9.	Distributor’s Financial Condition

 

		9.1	At OxySure’s sole discretion, OxySure may withhold shipments due to Distributor’s general
financial condition and/or conditions of Distributor’s account with OxySure. In the event Distributor is in arrears per Exhibit
D, OxySure may elect to place Distributor on credit hold, meaning no shipments will be made from OxySure to Distributor until such
arrearages are satisfied. In the event Distributor is in arrears for more than sixty (60) days, or if Distributor is placed on
credit hold more than twice in any twelve (12) month period, OxySure may declare Distributor to be in breach of this Agreement.

 

		9.2	If Distributor is placed on credit hold, OxySure may ship direct to Customers. OxySure will provide
Products to Customers at OxySure’s suggested resale price (unless OxySure is otherwise notified of a differing Distributor
resale price) (the “Customer Price”). The Customer will be billed directly by OxySure. For shipments made to fulfill
Customer orders submitted through Distributor, the difference between the Customer Price and the price OxySure sells to Distributor,
from the then-current Product Price List, will be applied against any Distributor arrearages (“Withholding”). No amounts
will be applied to arrearages if a Customer orders directly from OxySure or another distributor, even if Distributor typically
services that Customer’s account. Neither Withholdings nor shipments to existing Customers under the limited scope of this
provision will be construed as a breach of this Agreement. Direct shipments to Customers under this provision shall not relieve
Distributor of any obligations to further develop the Territory, Channel or the accounts therein, or support those Customers to
which the direct shipments are made.

 

		9.3	In the even OxySure elects to establish a credit account for the Distributor, Distributor will
provide OxySure with credit data sufficient to establish Distributor’s credit-worthiness. The decision to offer such a credit
account or to decline to establish such an account upon review of Distributor’s credit data is in the sole discretion of
OxySure. OxySure may periodically review Distributor’s credit worthiness and may withdraw any credit approval at any time,
at OxySure’s sole discretion.

 

		9.4	Distributor agrees to execute a UCC-1 financing statement, or similar instrument, for the purposes
of indicating OxySure’s financial interest in any outstanding account. OxySure shall have the sole responsibility of filing
such financing statement or similar instrument.  

 

	10.	Confidentiality/Non-Competition

 

		10.1	During the term of this Agreement, Distributor and its employees may have access to OxySure’s
Proprietary Information, such information, whether written or oral, being of a nature that OxySure desires to protect against unauthorized
use or disclosure. The term “Proprietary Information” shall include, but is not limited to, information relating to
research, marketing, developments, inventions, product lines, design, purchasing, finances and financial affairs, accounting, merchandising,
selling, engineering, employees, Customers, consultants, trade secrets, business practices, merchandise resources, supply resources,
service resources, system designs, procedure manuals, or pricing relating to the Products. The term Proprietary Information does
not include any information which is: (a) in the public domain or that enters the public domain without a breach of this Agreement;
(b) known by the receiving party prior to the disclosure; or (c) disclosed by a third party unrelated to or not in breach of this
Agreement, or subject to some other confidentiality agreement.

 

OxySure®
Distribution Agreement

    	Page 5 of 22

    	 

    

 

		10.2	Distributor will treat all Proprietary Information as proprietary and confidential. Distributor
shall not disclose any Proprietary Information to anyone other than its own employees, directors, and consultants. Distributor
shall further use reasonable efforts to prevent any unauthorized use or disclosure, including, but not limited to, restricting
access to the Information within its organization to those having a need to know and ensuring that everyone to whom it makes a
disclosure complies with this Agreement by entering into an agreement that imposes a like obligation with each person to which
a disclosure is made. Distributor will not disclose any information to any party not enumerated above without obtaining prior written
consent from OxySure.

 

		10.3	Without the prior written authorization of OxySure, Distributor agrees that during the term of
this Agreement and for a period of one (1) year thereafter, without regard to the party terminating this Agreement or the reason
for termination, if any, Distributor (which includes its employees, directors, officers, and consultants) will not in the United
States or in any foreign country in which OxySure® is then marketing its products or services, directly or indirectly
represent any manufacturer, market or sell, control an interest in or act as an officer, director, or employee of, or consultant
or adviser to, any firm, corporation, institution or entity, directly or indirectly involved in the manufacturing or distribution
of any products related to the catalytic generation of oxygen, as reasonably determined by OxySure® in its discretion.

 

		10.4	Without limiting the obligation in Section 2.14, Distributor shall comply with all privacy and
security laws relevant to the sale and distribution of Products and shall ensure that each employee, director, officer, and consultant
of Distributor complies with such privacy laws at all times.

 

		10.5	Within twenty (20) days from the written request from OxySure®, Distributor will
provide copies of any or all written agreements between Distributor and its employees, directors, officers, consultants, and parties
to which Proprietary Information has been disclosed by the Distributor made pursuant to the objectives of Sections 10.2, 10.3,
and 10.4.

 

		10.6	Distributor, upon termination of this Agreement, shall surrender to OxySure® all
Proprietary Information, (including: training manuals, marketing updates, product literature, price lists, and product samples),
whether originals, copies, English or non-English translations.

 

		10.7	Distributor acknowledges that the OxySure® may suffer irreparable damage in the
event of a breach or threatened breach of any provision of this Section 10, and that therefore, OxySure® may seek
injunctive relief to prevent such breach, as well as any and all other applicable remedies at law or equity, including the recovery
of damages. This Section 10.7 controls over any conflict between this Section 10.7 and Section 18.9.

 

		11.	OxySure Trademarks, Service Marks, and Trade Names; Intellectual Property

 

		11.1	OxySure® grants to Distributor a non-exclusive license to use OxySure’s trademarks,
trade names, and service marks only in connection with the Products and in the performance of Distributor’s obligations under
this Agreement. All such uses are subject to OxySure’s prior review and consent, which will not be unreasonably withheld
or delayed, and such license may be withdrawn or revoked at any time by OxySure® at its sole discretion, either
with or without cause.

 

		11.2	All use of OxySure’s trademarks, trade names, and service marks will be in proper form, giving
appropriate attribution to OxySure® as the owner of such marks. Distributor will not undertake any use of a mark
that may jeopardize OxySure’s rights to use or register such mark, or OxySure’s rights to prevent unauthorized use.

 

		11.3	All use of OxySure® trademarks, service marks, and trade names by Distributor will
inure to the benefit of OxySure®. At no time during or after the term of this Agreement shall Distributor attempt
to register any trademarks, service marks, or trade names confusingly similar to any OxySure® trademark, service
mark, or trade name. Distributor will cooperate, at OxySure’s expense, to assist OxySure® in the registration
or securing of rights in such marks. Distributor will cooperate, at OxySure’s expense, in initiating and prosecuting any
legal action against any infringer of any OxySure® trademark, service mark, or trade name.

 

OxySure®
Distribution Agreement

    	Page 6 of 22

    	 

    

 

		11.4	Distributor shall not, by reason of this Agreement or its provisions, acquire any interest in or
right to any patent, trademark, service mark, trade names, copyright, Proprietary Information or any other form of OxySure®
intellectual property, whether relating to the Products or otherwise.

 

		11.5	Any intellectual property, and any applications or methods related to any intellectual property,
developed or discovered by either party, jointly or individually, under this Agreement or relating to the Products (including,
but not limited to, patentable and/or copyrighted materials) are owned by OxySure®, and Distributor hereby assigns
and conveys all rights, title and interest in such intellectual property to OxySure. At OxySure’s request, Distributor shall
execute any instruments and documents necessary to confirm OxySure’s ownership of the intellectual property.

 

		12.	Relationship Between the Parties

 

		12.1	Distributor and OxySure®
intend to act and perform as independent contractors, and the provisions hereof are not intended to create any partnership, joint
venture, agency or employment relationship between the parties. Each party shall be solely responsible for and shall comply with
all state and federal laws pertaining to employment taxes, income withholding, unemployment compensation contributions and other
employment related statutes applicable to that party.

 

		12.2	Neither party has any authority to act for and/or to bind the other party in any way, or to represent
that either is in any way responsible for the acts of the other.

 

		13.	No Conflicts by Distributor

 

Distributor warrants and represents
that Distributor is not subject to any contractual obligation or restraint which will interfere with Distributor’s right
and ability to perform pursuant to the terms of this Agreement.

 

		14.	Defaults; Remedies; and Termination

 

		14.1	Either party may terminate this Agreement immediately by sending written notice if the other party
becomes insolvent, or becomes the subject of any proceeding seeking relief, reorganization, or rearrangement under any laws relating
to bankruptcy or insolvency, or upon any assignment for the benefit of creditors, or upon the appointment of a receiver, liquidator,
or trustee of any of its property or assets, or upon the liquidation, dissolution, or winding up of its business.

 

		14.2	OxySure may terminate this Agreement immediately by sending written notice upon the assumption
of control of Distributor by a governmental authority or other third party; the sale or transfer of the majority or all of its
assets; or if there is a change of control, ownership, or management of the Distributor.

 

		14.3	This Agreement may be terminated by the mutual agreement of OxySure and the Distributor.

 

		14.4	If either party breaches any commitment contained in or arising from this Agreement (excepting
Sections 14.1 and 14.2) and fails to remedy the breach within thirty (30) days from the date of written demand to cure (provided,
however, in the event of Distributor’s default in its obligations under Article 4, there shall be no such demand required
or cure available), the breaching party shall be deemed to be in default hereunder.

 

(a) On Distributor’s
default, OxySure may do any of the following, as determined in OxySure’s sole discretion: (i) declare any unpaid sums under
this Agreement immediately due and payable; (ii) suspend further performance by OxySure; (iii) terminate this Agreement; (iv) cancel
the Distributor’s distribution rights; (v) reduce the extent of the Territory and/or Channel; and/or (vi) commence a legal
proceeding, in accordance with Section 18.9, for damages and/or specific performance and/or pursue any and all other available
remedies at law or in equity, all of such remedies being cumulative of each other.

 

OxySure®
Distribution Agreement

    	Page 7 of 22

    	 

    

 

(b)
In reviewing the Distributor’s performance in accordance with the Distributor’s obligations under Article 4, the parties
agree that OxySure® shall not be limited to semi-annual determinations but may make a determinative evaluation of
semi-annual performance based upon a two month pro rata analysis based on at least two consecutive months.

 

		(c)	In reviewing the Distributor’s performance in accordance with the Distributor’s obligations
under Sections 2.2 and 2.4 and/or Article 4, the parties agree that OxySure shall not be limited to assessing the Distributor’s
performance within the Territory and Channel as a whole. Accordingly, OxySure can evaluate the Distributor’s performance
based on the Territory or Channel as a whole or on any definable sub-territory or sub-channel (e.g., state boundaries, county boundaries,
municipal boundaries, Customer, etc.).

 

		(d)	In reviewing Distributor’s financial condition under Section 9, the parties agree that OxySure
may monitor Distributor’s credit through a variety of sources and means, including commercial credit companies. Accordingly,
a determination of credit worthiness may be based on third-party sources instead of and/or in addition to Distributor’s accounts
and payment history with OxySure.

 

		14.5	Either party may terminate this Agreement at any time prior to the expiration of the then-applicable
term, without cause, by sending written notice to the other party at least ninety (90) days prior to the termination date.

 

		14.6	Intentionally left blank.

 

		14.7	Termination of this Agreement terminates all further rights and obligations of OxySure and Distributor
hereunder other than the following obligations and sectional provisions, all of which shall survive any termination of this Agreement:

 

		(a)	Neither OxySure nor Distributor shall be relieved of their respective obligations to pay any money
due the other party; and

 

		(b)	Sections: 7 (Limited Warranty), 8 (Reports and Audits), 10 (Confidentiality/Non-Competition), 14
(Defaults; Remedies; and Termination); 15 (Indemnity and Insurance), 16 (Limitation of Liability), 17 (Intellectual Property Indemnification),
18.7 (Governing Law), and 18.9 (Negotiation, Mediation and Arbitration).

 

		14.8	On termination of this Agreement for whatever cause, Distributor will immediately (a) cease to
engage in marketing and distribution activities as an OxySure distributor, and (b) cease representing in any manner that it is
a distributor of OxySure Products, including the immediate termination of all use of OxySure® trademarks, service
marks, or trade names. Notwithstanding Distributor agrees that if OxySure so requests after the termination of this Agreement,
Distributor shall pay for and distribute orders for Products which OxySure received and accepted during the term of this Agreement.

 

		15.	Indemnity and Insurance

 

		15.1	Distributor agrees to indemnify and hold OxySure harmless from any and all claims, demands, costs,
liabilities and responsibilities, regardless of the claimant or his place of filing a claim, to the extent such result from or
are associated with Distributor’s alleged negligent or intentional acts or omissions, any default by Distributor under this
Agreement, or the provision of any warranty or guarantee of the Products given by the Distributor.

 

		15.2	Distributor will maintain product liability insurance or the like for those claims enumerated in
Section 15.1.

 

		15.3	OxySure® agrees to indemnify and hold Distributor harmless from any and all third
party claims and demands to the extent they result from defective Products provided by OxySure® to Distributor or
the provision of any express warranty or guarantee of the Products prepared and provided by OxySure to a Customer. Distributor
shall promptly notify OxySure® of any such claim and demand, shall provide reasonable assistance to OxySure in the
defense of such claims and demands, and shall give OxySure full authority to defend, settle or resolve the claims or demands on
behalf of Distributor.

 

		16.	Limitation of Liability

 

In no event shall OxySure be liable
to Distributor for any indirect, punitive, consequential, special, incidental or loss of profit damages.

 

OxySure®
Distribution Agreement

    	Page 8 of 22

    	 

    

 

		17.	Intellectual Property Indemnification

 

		17.1	Distributor agrees that OxySure® has the right to, and OxySure agrees that it will,
at its sole cost and expense, defend or at its option, settle any claim, suit, proceeding, or other action brought against Distributor
or its Customers for infringement of any United States copyright, trademark, or other United States intellectual property right
related to the Products or their use, subject to the limitations set forth in Sections 17.2 and 17.3. OxySure shall have sole control
of any such proceeding or settlement negotiations in order to be held liable. OxySure will not be liable for any costs, settlements
or expenses incurred without its prior written authorization. OxySure will pay any final judgment entered against Distributor or
its Customers based on such infringement provided OxySure had sole and complete control of the proceeding.

 

		17.2	OxySure will be relieved of its obligations under Section 17.1 unless Distributor or its Customers
notify OxySure, in writing, of such action, within three (3) days of its receipt of notice of same and gives OxySure full information
and assistance to settle and/or defend any such action. If relieved of its obligation under Section 17.1, OxySure may assume such
obligation upon written notice to the Distributor.

 

		17.3	OxySure assumes no liability for, and Distributor agrees to indemnify and hold OxySure harmless
to the same extent as that indemnification identified in Section 17.1, for:

 

(a) any infringements
covering completed equipment or any assembly, combination, or method in which any of the Products may be used, but not covering
such Products standing alone; or

 

(b) any trademark
infringement involving any marketing or branding not applied by OxySure or involving any marking or branding applied at the request
of Distributor; or

 

(c) any modification
of the Products unless such modification was made by OxySure®.

 

		18.	General Provisions

 

		18.1	Entire Agreement. This Agreement, which includes the Exhibits, sets forth the entire agreement
and understanding of the parties relating to the subject matter herein and supersedes all prior discussions between them whether
written or oral. The following Exhibits are attached hereto and made a part hereof for all purposes:

 

	 	Exhibit Letter	 	Name of Exhibit	 
	 	A	 	Description of Products	 
	 	B	 	Description of Territory and Channel	 
	 	C	 	Minimum Net Sales	 
	 	D	 	Payment Terms	 
	 	E	 	Return Goods Policy	 
	 	F	 	Limited Product Warranty	 
	 	G	 	Pricing & Discount Schedule	 
	 	H	 	Internet Distribution Attachment	 

 

		18.2	Assignment. Distributor may not assign or transfer its right under this Agreement without
the prior written consent of OxySure®.

 

		18.3	Modifications and Waiver. This Agreement may be modified only in writing, signed within
the authority granted by each party, and shall not be modified, varied, superseded or construed in a particular manner due to any
course of conduct, trade usage, custom or dealing or any statute or common law. It is expressly agreed and understood that the
waiver by a party of its rights, or any portion of its rights, under this Agreement in any particular instance or instances, whether
intentional or otherwise, shall not be construed as a continuing waiver which would prevent the subsequent enforcement of such
rights, or as a waiver of any other rights hereunder.

 

		18.4	Headings. The headings of this Agreement are for convenience of reference only, and are
not intended to be part of or to affect the meaning or interpretation of this Agreement.

 

		18.5	Notices. All notices under this Agreement shall be deemed sufficient if sent by certified
or registered mail (postage prepaid) with return receipt requested, overnight or air courier, facsimile, telex, or cable to the
party, at the addresses identified herein, to whom such notice is required or permitted to be given. Any such notice shall be deemed
to have been received on the next business day after transmission by facsimile, telex, cable or overnight or air courier, and on
the third business day after transmission by certified or registered U.S. mail, return receipt requested.

 

OxySure®
Distribution Agreement

    	Page 9 of 22

    	 

    

 

		18.6	Severability. Whenever possible, each provision of the Agreement shall be interpreted in
such a manner as to be effective and valid under applicable law, but if any provision of the Agreement should be prohibited or
invalid, in whole or in part, under applicable law, such provisions shall be ineffective only to the extent of such prohibition
or invalidity without invalidating the remainder of such provision or the remaining provisions of this Agreement.

 

		18.7	Governing Law. This Agreement is governed by the substantive laws of the State of Texas,
U.S.A. Any actions related to this Agreement must be brought in the courts located in Dallas County, State of Texas.

 

		18.8	Language Construction. The language in all parts of this Agreement shall be construed, in
all cases, according to its fair meaning, and not for or against either party hereto. The parties acknowledge that each party and
its counsel have reviewed and revised this Agreement and that the normal rule of construction to the effect that any ambiguities
are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement

 

		18.9	Negotiation, Mediation, and Arbitration. The parties will attempt in good faith to resolve
any controversy or dispute arising out of or relating to this Agreement promptly by negotiations between or among the parties.
If any party reaches the conclusion that the controversy or dispute cannot be resolved by unassisted negotiations, such party may
notify the American Arbitration Association (“AAA”), 140 West 51st Street, New York, New York 10020 [telephone (212)
484-3266; fax (212) 307-4387]. AAA will promptly designate a mediator who is independent and impartial, and AAA’s decision
about the identity of the mediator will be final and binding. The parties agree to conduct mediated negotiations in Dallas, Texas,
within thirty (30) days after the notice of mediation is sent. If the dispute is not resolved by negotiation or mediation within
thirty (30) days after the first notice to AAA is sent, then, upon notice by any party to the other affected parties and to AAA,
the controversy or dispute shall be submitted to a sole arbitrator who is independent and impartial, selected in accordance with
the rules of the AAA, for binding arbitration in Dallas, Texas, in accordance with AAA’s Commercial Arbitration Rules. The
arbitration shall be governed by the United States Arbitration Act, 9 U.S.C. Sections 1-16 (or by the same principles enunciated
by such Act in the event it may not be technically applicable).

 

The parties agree that they will
faithfully observe this Agreement and will abide by and perform any award rendered by the arbitrator. The award or judgment of
the arbitrator shall be final and binding on all parties. No litigation or other proceeding may be instituted in any court for
the purpose of adjudicating, interpreting or enforcing any of the rights or obligations relating to the subject matter hereof,
whether or not covered by the express terms of this Agreement, or for the purpose of adjudicating a breach or determination of
the validity of this Agreement, or for the purpose of appealing any decision of an arbitrator, except a proceeding instituted for
the sole purpose of having the award or judgment of an arbitrator entered and enforced or for the sole purpose of seeking a temporary
restraining order or temporary or permanent injunction (provided, that any damages or costs issues shall not be decided by any
court hearing such petition but shall be adjudicated in accordance with the mediation and arbitration procedures set forth herein).
If any party becomes the subject of a bankruptcy, receivership or other similar proceeding under the laws of the United States
of America, any state or commonwealth or any other nation or political subdivision thereof, any factual or substantive legal issues
arising in or during the pendency of any such proceeding shall be subject to all of the foregoing mandatory mediation and arbitration
provisions and shall be resolved in accordance therewith.

 

The Agreements contained herein
have been given for valuable consideration, are coupled with an interest and are not intended to be executory contracts. Section
10.7 controls over any conflict between Section 10.7 and this Section 18.9.

 

OxySure®
Distribution Agreement

    	Page 10 of 22

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed by their respective authorized representatives or officers, effective as of the day and year
indicated above.

 

	DISTRIBUTOR:	 	OxySure®Systems, Inc.:
	 	 	 	 	 
	Name: 	 	OxySure® Systems, Inc..
	Company:  	 	10880 John W. Elliott Drive, Suite 600
	Address  	 	Frisco, Texas, 75034 USA
	 	 	 	PH:(+1) 972-294-6450
	PH:       	 	FAX:(+1) 972-294-6501
	FAX:	 	EMAIL: jross@oxysure.com 
	EMAIL:	 	 	 
	 	 	 	 
	By:	 	 	By:	 
	Title:	 	 	 	Julian Ross
	 	 	 	 	Chairman and CEO
	 	 	 	 
	Date:	 	 	Date:	 

 

OxySure®
Distribution Agreement

    	Page 11 of 22

    	 

    

 

EXHIBIT A

Products 

 

The Products shall be defined as all OxySure® products
and accessories for such products, including (but not limited to)

 

	Part 

Number	Description
	615-00  	Model 615 Portable Emergency Oxygen Unit, complete system
	615-01 	Model 615 Replaceable Cartridge w/Mask
	615-02 	Replacement Adult Mask 
	615-03	Replacement Pediatric Mask
	615-04	Display Cabinet with Alarm and Emergency Oxygen marking
	615-05	Custom (Emergency Oxygen) Wall-mounted Display Cabinet w/Alarm
	615-07	OxySure Wall Sign
	615-09	OxySure Thermal Bag
	615-10	Resuscitator Bag, Adult
	615-11	Resuscitator Bag, Pediatric
	615-12	Pulse Oximeter – Standard
	615-13	Pulse Oximeter – Premium
	615-15	Combination Wall Mount Cabinet for OxySure and AED

 

OxySure®
Distribution Agreement

    	Page 12 of 22

    	 

    

 

EXHIBIT B

 

Territory and Channel

 

1.The Territory is defined as (check all that apply):

 

		☐	The following areas within the United States:

 

			______NA_______________________________

 

			________________________________________

 

			________________________________________

 

		☒	The following countries (requires Attachment B-1, International Terms, to be attached):

 

	 	 	SAUDI ARABIA
			________________________________________
			________________________________________
	 	 	 
	 	 	If the Territory includes any
country other than the United States, Distributor hereby consents to and is bound by the terms of Attachment B-1, International
Terms.

 

2.The Channel is defined as:

 

All non-retail and retail channels.

 

OxySure®
Distribution Agreement

    	Page 13 of 22

    	 

    

 

ATTACHMENT B-1

International Terms

 

If the Territory includes any country other
than the United States, then this Attachment B-1 will be incorporated into and made part of the Distribution Agreement between
OxySure and Distributor. All capitalized terms not defined in this Attachment have the definitions set forth in the Distribution
Agreement

 

1.Distributor shall be responsible for
translating at its expense all marketing and promotional materials provided by OxySure, including any manuals, into the language
or languages used in the Territory. Distributor shall promptly deliver to OxySure a copy of such translation in the formats reasonably
requested by OxySure. Such translations will be deemed a “work for hire” as such term is used in United States copyright
law, and OxySure will be considered the author and owner of all rights in and to such translation. To the extent the translation
is not a work for hire, Distributor hereby assigns to OxySure, and agrees that OxySure will have, all ownership rights in the manuals
and translations created or provided by Distributor. Distributor shall provide all documentation (including written assignments)
reasonably requested by OxySure® to confirm its ownership of the manuals and translations. Distributor shall make
such changes to the marketing and promotional materials as are required to comply with the law of the countries, or political subdivisions
in the Territory, but only with the prior approval of OxySure. Ownership of all marketing and promotional materials remain with
OxySure.

 

2.OxySure shall use commercially reasonable
efforts to ship Products sold hereunder within the period and by a carrier designated in each accepted purchase order, and FOB
the relevant OxySure® facility determined by OxySure. Distributor shall be responsible for obtaining all licenses
required to import Products into the Territory. OxySure® shall be responsible for obtaining all licenses required
to export products from the United States. All freight, transportation, rigging, crating, packing, drayage, insurance, and handling
charges, as well as any other expenses that are not specifically allocated to OxySure in this Attachment B-1, will be paid by Distributor.
Title, possession and risk of loss shall pass to Distributor upon delivery of the Products by OxySure to the designated carrier
or freight forwarder.

 

3.OxySure® and Distributor
agree that if it is required by applicable law, this Agreement shall be approved by and/or registered with the appropriate governmental
authorities. The rights and obligations of OxySure® and Distributor under this Agreement are subject to any such
government approval, registration or recordation, including import and export certificates (“Approvals”). Distributor
is responsible and shall bear the cost for promptly obtaining and maintaining any such Approvals from requisite government agencies
in the Territory for Distributor and OxySure to advertise, market, sell, distribute, license, and support the Products in the Territory.
To the extent additional Approvals are required for new or existing OxySure® Products, or to the extent countries
other than those set forth in the Territory are now or hereafter included in the Territory, then Distributor shall bear the sole
cost and responsibility for promptly obtaining such Approvals, including compliance with all local content requirements, effective
as of the date of this Agreement, or as such requirements may subsequently be modified. All costs of compliance, and whatever actions
may be required (whether legal, manufacturing, assembly or otherwise) shall be the sole financial responsibility and obligation
of Distributor. To the extent any governmental approval would require OxySure® to change or modify its Products,
OxySure® shall have no obligation to do so, and may at its discretion terminate this Agreement with Distributor
with no further obligation hereunder, in order to avoid the threat of non-compliance with governmental regulations. Distributor
agrees that it shall not submit any information to governmental authorities with respect to this Agreement without the prior written
approval of OxySure®; provided however, that the foregoing shall not apply in the event that formal or informal
proceedings are instituted against Distributor or in the event that a dispute between OxySure and Distributor is submitted to any
tribunal having jurisdiction over such matters.

 

4.Distributor shall provide OxySure with
evidence of all government permits, certificates or approvals. Distributor shall provide to OxySure promptly upon its request such
evidence as OxySure® shall require, including, but not limited to, an opinion of counsel of the Territory (which
counsel must be approved by OxySure in its sole discretion although the costs of such opinion shall be borne by Distributor), of
compliance by Distributor with the applicable import regulations of jurisdictions within the Territory or any other applicable
jurisdiction, including those governing the filing of proper import documentation and the payment of all duties and fees of any
nature whatsoever required for such import.

 

OxySure®
Distribution Agreement

    	Page 14 of 22

    	 

    

 

5.Distributor shall comply with, and Distributor
shall require its Customers to comply with, the United States Export Administration Act, the United States Anti-Boycott provisions
and the United States Foreign Corrupt Practices Act (“FCPA”), as well as all applicable statutes, rules and regulations
in the United States and the Territory, as the same may be amended from time to time. Distributor represents and warrants to OxySure
that it is familiar with the terms and provisions of the FCPA and the purposes of the FCPA. Distributor further represents and
warrants that (a) except as otherwise disclosed in writing to OxySure® prior to execution of this Agreement, neither
it nor any of its owners, staff members or Affiliates are officials, officers or representatives of any government or candidate
for political office, and (b) that no part of the proceeds from sales of the Products will be used by it for any purpose or to
take any action which will constitute a violation of any law of any government in the Territory or any part thereof or the United
States, including the FCPA.

 

6.This Agreement is an international transaction
for the sale of goods in which the specification of United States Dollars and payment in Frisco, Texas is of the essence and United
States Dollars shall be the currency of account in all events. The payment obligations of distributor shall not be discharged by
an amount paid by Distributor in another currency or at another place, whether pursuant to a judgment or otherwise, to the extent
that the amount so paid on prompt conversion to United States Dollars and transferred to Frisco, Texas under normal banking procedures
does not yield the amount of United States Dollars in Frisco, Texas due hereunder. If any payment by Distributor, whether pursuant
to a judgment or otherwise, upon conversion and transfer does not result in payment of such amount of United States Dollars due
hereunder in Frisco, Texas, Distributor shall compensate OxySure for the additional amount necessary to yield the amount due and
owing to OxySure.

 

7.Distributor agrees specifically that
it will not directly or indirectly export or re-export the Products or any technical data or service that is the direct product
of the Products to any country outside the Territory without the written permission of OxySure.

 

8.The parties expressly agree that the
International Convention for the Sale of Goods will not apply to this Agreement.

 

9.The parties agree to mutually cooperate,
one with the other, in notifying the other parties of any laws or of any changes in their respective domestic laws or laws of the
Territory which might impact on any purchase orders, this Agreement or its exhibits, including but not limited to export/import
controls, currency restrictions, competition requirements, and technology/licensing transfers.

 

10.This Agreement (including any exhibits
or attachments hereto) shall be executed in English only. If any dispute or question of interpretation concerning this Agreement
or any other materials related to this Agreement arises, the provisions of the English language version shall control.

 

	DISTRIBUTOR: 	OxySure® Systems, Inc.:
	 	 	 	 	 
	By:	 	 	By:	 
	
         

        Title:
	 	 		 
	 	 	 	 	 
	Date:	 	 	Date:	 

 

OxySure®
Distribution Agreement

    	Page 15 of 22

    	 

    

 

EXHIBIT C

Minimum Net
Purchases

 

During the Initial Term: Distributor shall purchase a minimum
of 2,000 Units of Model 615 (Part Number 615-00) per annum (averaged over the first three (3) years of the agreement), or
the dollar equivalent thereof in purchases; plus a minimum of 4,000 Units of Model 615 Replaceable Cartridge w/Mask (Part Number
615-01) per annum (averaged over the first three (3) years of the agreement)

 

Thereafter, for each Renewal Term, the Minimum
Net Purchases shall be agreed to by the Parties pursuant to Section 4 of the Agreement, but in no event shall the annual minimum
purchase during each Renewal Term be less than the number of units sold during the Initial Term.

 

OxySure®
Distribution Agreement

    	Page 16 of 22

    	 

    

 

EXHIBIT D

Payment Terms

  

Payment in advance of shipment.

 

OxySure®
Distribution Agreement

    	Page 17 of 22

    	 

    

 

EXHIBIT E

 

THE FOLLOWING POLICY AND PROCEDURE ARE APPLICABLE
TO THOSE PRODUCTS TO WHICH A LIMITED WARRANTY DOES NOT APPLY, THE PROVISIONS HEREINBELOW ARE TO BE CONSTRUED IN A MANNER CONSISTENT
WITH THE TERMS AND CONDITIONS OF THE AGREEMENT AND DO NOT REPRESENT ADDITIONAL WARRANTIES, GUARANTIES OR REPRESENTATIONS:

 

		1.	Before any product may be returned, a Return Materials Authorization number (RMA#) must
be secured. RMA#’s can only be issued by OxySure’s Customer Service.

 

			To assist in the return process, the Customer/Distributor is required to provide Customer Service
the following information:

 

			(a) OxySure Product Code and Lot Number

 

			(b) Quantity Customer/Distributor Wishes to Return

 

			(c) Order Number Associated with the Products

 

			(d) OxySure’s Original Invoice Number

 

			(e) Reasons for Return

 

		2.	All Products returned shall be shipped to OxySure, freight prepaid, unless the return is due to
OxySure® error, such determination being made in OxySure’s sole discretion. On all international returns,
OxySure® will specify the method of shipment.

 

		3.	Items eligible for full credit:

 

(a) Products shipped in error.

 

(b) Products ordered in error, if
authorized for return within thirty (30) days of receipt.

 

(c) Defective Products due to OxySure®
workmanship.

 

		4.	Items not eligible for return:

 

		(a)	Custom products or products sold on a “No-return” basis.

 

		(b)	Goods held over ninety (90) days from the original Invoice Date.

 

		(c)	Partial cases or quantities less than minimum order quantity.

 

		(d)	Products unsalable due to re-design, preprocessing, revision, or obsolescence.

 

		(e)	Demonstration products.

 

		(f)	Products no longer in their original packaging, used, or damaged through no fault of OxySure®.

 

		5.	A 20% Restocking Fee will be assessed on all returns authorized over (thirty (30) days)
after the original Invoice Date.

 

OxySure®
Distribution Agreement

    	Page 18 of 22

    	 

    

 

EXHIBIT F

Limited Product Warranty

 

Refer to the Product literature packaged with
each Product, such being incorporated by reference herein, for any applicable Customer limited warranty.

 

OxySure®
Distribution Agreement

    	Page 19 of 22

    	 

    

 

EXHIBIT G

Pricing Schedule

 

	 	MSRP	Volume Range Min	Volume Range Max	Unit Price, Authorized
	 	 	#Units	#Units	Distributors Only
	 	 	 	 	 
	Model 615, Base Systems (SKU 615-00)1:	 	 
	 	$349.003 	1 	+
	$209.00
	 	 	 	 	 
	Model 615, Cartridges (SKU 615-01)2:	 	 
	 	$149.003 	1 	+
	$101.00

 

	Model 615, Mask/Tray (SKU 615-03):	 	 
	 	$25.00 	1
	499
	$14.50
	 	 	 
	Model 615, Pediatric Mask/Tray (SKU 615-04):
	 	$27.50 	1
	499
	$15.00
	 	 	 	 	 
	Custom (Emergency Oxygen) Wall-mounted Display Cabinet (SKU 615-05):
	 	$349.00 	 1 	 50 	209.40
	 	 	 	 	 
	OxySure Wall Sign (SKU 615-07):
	 	$18.95 	1	+	$10.00
	 
	OxySure Thermal Bag (SKU 615-09):
	 	$89.00 	1	+	$55.00
	 
	Resuscitator Bag, Adult (SKU 615-10):
	 	$36.00 	1	+	$24.00
	 
	Resuscitator Bag, Pediatric (SKU 615-11):
	 	$38.00 	1	+	$25.00
	 
	Pulse Oximeter – Standard (SKU 615-12):
	 	$99.00 	Min order qty=12	+	$67.00
	 
	Pulse Oximeter – Premium (SKU 615-13):
	 	$129.00 	Min order qty=12	+	$87.50
	 	 	 	 	 
	Pulse Oximeter – Premium (SKU 615-13):
	 	$369.00	1	+	$219.00

 

Notes: (1) Model 615 is shipped “Rescue Ready,” and
includes a cartridge and adult mask. (2) Replacement Cartridges come with standard Adult masks. (3) These products are subject
to a MAP (Minimum Advertised Pricing).

 

Volume refers to purchase order volume. All Prices are FOB Frisco,
Texas, USA.

 

OxySure®
Distribution Agreement

    	Page 20 of 22

    	 

    

 

EXHIBIT H

Internet Distribution Attachment

 

To be effective, this Internet Distribution
Attachment must be signed by both OXYSURE® SYSTEMS, INC. (“OxySure” or “OxySure®”),
and  (the “Distributor”). Once effective, this Exhibit H will be incorporated into and made part
of the Distribution Agreement between OxySure® and Distributor. All capitalized terms not defined in this Attachment
have the definitions set forth in the Distribution Agreement.

 

1.Effective Date. This Internet
Distribution Attachment is effective as of _____________________________.

 

2.Internet Promotion and Distribution.
This Internet Distribution Attachment governs all promotion, sale, advertising, marketing and other offers made via electronic
means, including via the Internet. Internet promotions includes the following: (a) offering or displaying the Product through any
online channel, including but not limited to via the Web (HTTP), RSS, FTP, or other method, (b) email offers to multiple individuals
or companies, (c) promotions and advertising embedded or appearing in software products, (d) promotions and advertising embedded
in or associated with streaming or downloadable media, including audio and video media, and (e) any other methods or means similar
or related to those currently available via the Internet.

 

3.Distributor’s Promotion.
Distributor intends to promote, sell, advertise, market and otherwise offer the Products through the following websites and methods:

 

___________________________________________________________________________________

 

___________________________________________________________________________________

 

___________________________________________________________________________________

 

___________________________________________________________________________________

 

Distributor and OxySure® may
add additional websites and methods by mutual written agreement.

 

Distributor shall be solely responsible for
all costs and charges associated with its Internet promotion, including all server and bandwidth charges.

 

4.Territory.
Distributor shall implement technological and other measures to ensure that Products are not (a) promoted outside of the Territory,
or (b) shipped outside of the Territory. Such measures may include page access denial for IP addresses outside the Territory, a
prominent disclaimer on the Product page stating that Products will not be shipped outside the Territory, and canceling orders
to be shipped to addresses outside the Territory.

 

5.Pricing. To the extent
the pricing offered by Distributor through an Internet promotion is lower than the Manufacturer Suggested Retail Price, Distributor
shall ensure that (a) the price may be viewed only by users on Distributor’s website that have logged in using a valid username
and password, and (b) the price is not distributed via email, except in response to a valid inquiry requesting the price.

 

6.Photos and Graphics. Any
Product photos or graphics used in an Internet promotion must accurately depict the Product, and must clearly display all trademarks
that actually appear on the Product. Distributor may use Product photos provided by OxySure®, so long as such photos
are not altered in any manner and all copyright notices appearing on the photo remain intact.

 

7.Manuals and Documentation.
Distributor may not post any photos, scans or other versions of Product manuals or other documentation related to the Products
without the prior written consent of OxySure®.

 

8.Product Reviews. Distributor
may allow Customers to post reviews of the Product, provided that Distributor will remove any Product review that OxySure reasonably
believes is false, misleading, or not supported by verifiable evidence.

 

OxySure®
Distribution Agreement

    	Page 21 of 22

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have
caused this Internet Distribution Attachment to be executed by their respective authorized representatives or officers, effective
as of the day and year indicated above.

 

	DISTRIBUTOR:
    	OxySure®
    Systems, Inc.:
	 	 	 	 	 
	By:	 	 	By:	 
	
         

        Title:
	 	 		 
	 	 	 	 	 
	Date:	 	 	Date:	 

 

 

OxySure®
Distribution Agreement

Page 22 of 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]